Research and Markets: FDA US Regulatory Trends During 2010: A Rapidly Changing Environment

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/a8f582/us_regulatory_tren) has announced the addition of the "US Regulatory Trends During 2010: A Rapidly Changing Environment" report to their offering.

The US Food and Drug Administration (FDA) approved 21 new molecular entities (NMEs) in 2010, the lowest since 18 new drugs were approved in 2007. Despite this drop in registrations, BMI notes that five potential blockbusters received approval during 2010, highlighting promising revenue growth opportunities for the drugmakers concerned: Genentech, Novo Nordisk, Amgen, Novartis and Dendreon.

Of the potentially new blockbuster drugs approved, most are biological therapies, including Agmen's Prolia (denosumab) to treat osteoporosis in menopausal women, Genentech's Actemra (tocilizumab) to treat rheumatoid arthritis, and Dendreon's Provenge (sipuleucel-T), an immunetherapy for prostate cancer.

For more information visit http://www.researchandmarkets.com/research/a8f582/us_regulatory_tren.



CONTACT:

Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Oncology  Pharmaceutical  Professional Services  Other Professional Services  FDA

MEDIA:

Logo
 Logo

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.